Syndax Pharmaceuticals Inc header image

Syndax Pharmaceuticals Inc

SNDX

Equity

ISIN null / Valor 24112479

NASDAQ (2026-09-04)
USD 20.56-0.58%

Syndax Pharmaceuticals Inc
UMushroom community rating:

star star star star star
4.28 18 votes No rating yet
NegativeNeutralPositive

About company

Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cancer treatment. The company aims to extend and improve the lives of cancer patients by leveraging cutting-edge scientific research and advancements. Syndax collaborates with various stakeholders in the medical and scientific communities to identify and develop promising drug candidates. The company's pipeline includes treatments designed to address unmet medical needs in oncology, with a particular emphasis on novel mechanisms of action and overlooked aspects of cancer biology. Through these efforts, Syndax seeks to bring new, effective treatment options to market, enhancing patient outcomes and advancing the field of cancer therapy.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

27.0%1Y
5.17%3Y
15.2%5Y

Performance

51.0%1Y
58.0%3Y
55.6%5Y

Volatility

Market cap

1836 M

Market cap (USD)

Daily traded volume (Shares)

1,360,749

Daily traded volume (Shares)

1 day high/low

12.75 / 12.4

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.28

18 votes
Performance:
starstarstarstarstar
3.94
Innovation:
starstarstarstarstar
4.33
Society:
starstarstarstarstar
4.44
Nature:
starstarstarstarstar
4.17
Liam Hawkeswood
Switzerland, 18 Nov 2025
star star star star star
Liam Hawkeswood
Switzerland, 11 Nov 2025
star star star star star
****** Panggabean
UK, 09 Nov 2025
star star star star star
High risk and volatile performance. However, it has high upside potential and people are anticipating future returns

EQUITIES OF THE SAME SECTOR

Haemonetics Corp
Haemonetics Corp Haemonetics Corp Valor: 937449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 102.92
Align Technology Inc
Align Technology Inc Align Technology Inc Valor: 1159441
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.76%USD 158.63
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.13%SEK 454.80
Indivior PLC
Indivior PLC Indivior PLC Valor: 121550831
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.35%GBP 25.85
Vitrolife AB
Vitrolife AB Vitrolife AB Valor: 41707777
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.50%SEK 95.00
Camurus AB
Camurus AB Camurus AB Valor: 30510553
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.17%SEK 587.00
DBV Technologies SA
DBV Technologies SA DBV Technologies SA Valor: 2857349
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.54%EUR 2.31
CVS Group PLC
CVS Group PLC CVS Group PLC Valor: 3457960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 13.16
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.13%USD 86.35
Neumora Therapeutics Inc
Neumora Therapeutics Inc Neumora Therapeutics Inc Valor: 129329732
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.96%USD 1.31